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Introduction: 
In recent years, the anti-tumour potential of 
cannabinoids has highlighted the importance 
of this system in the generation of new anti-
cancer therapies (Freimuth et al., 2010; Patsos 
et al., 2005). The aim of the present study was 
to investigate the potential anti-tumour activity 
of a cannabinoid extract rich in cannabidivarin 
on breast tumour cells. 
Methods: 
MCF-7 cells (American Type Culture 
Collection) were grown and maintained in 
RPMI 1640 medium supplemented with 10% 
fetal bovine serum at 37oC, 5% CO2 .The 
cells were plated in 96-well culture plates at a 
density of 1x104 cells/well and allowed to 
adhere at 37oC for 24 hours. The following 
day, various doses of  extract  in the absence 
and presence of AM251, SR144528 and 
capsazepine, were added to the cells and 
further incubated for 4 days.  Then the 
supernatant was removed and MTT (3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide)   was added for 4 hours. The ability 
of cells to form formazan crystals by active 
mitochondrial respiration was determined by 
using a Microplate reader after dissolving the 
crystals in DMSO. Cytotoxicity was expressed 
as a relative percentage of the absorbance 
measured at 540 nm in the control and extract-
treated cells. Data were presented as the 
mean + s.e.mean and analysed using ANOVA 
followed by Dunnet’s t-test; Each point 
represents the mean of 4 separate 
experiments of 8 readings for each dose. 
Results: 
The extract induced dose-dependent 
cytotoxic effects on MCF-7 cells with an IC50 
of 0.067 mg/ml. Pre-treatment with AM251, 
SR144528 and Capsazepine, CB1, CB2 and 
TRPV1 receptor antagonists, respectively, 
did not reverse the cytotoxicity afforded by 
the extract. Interestingly, the cytotoxicity was 
potentiated by the application of AM251 with 
an  IC50 of 0.017+ 0.01 mg/ml. Single 
application of antagonists alone or vehicle 
did not affect the survival rate of the MCF7 
cells. (Figure1).  
 
Conclusion: 
The data suggest the unlikely involvement of 
CB1, CB2 and TRPV1 receptors in mediating  
extract-induced anti-tumour activity in  MCF-
7 tumour cells. Further experiments are 
required to investigate the receptor 
type/subtypes involvement and the 
mechanism of cell death. 
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Figure 1. The effect of CBDV on MCF-7 in the 
absence and presence of CB antagonists.  
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